Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 72.9%

Key Points

• Short interest in Inventiva S.A. has fallen by 72.9%, dropping from 36,900 shares to 10,000 shares by the end of July, indicating a potential shift in investor sentiment.
• A hedge fund, Wealth Enhancement Advisory Services LLC, recently acquired a stake in Inventiva, purchasing 10,715 shares valued at around $32,000.
• Despite these developments, Inventiva's stock is down 3.6% amidst regular trading, reaching $4.07, although it has a 52-week range between $1.53 and $4.36.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - ) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 10,000 shares, adropof72.9% from the July 15th total of 36,900 shares. Based on an average trading volume of 20,800 shares, the days-to-cover ratio is presently 0.5 days. Currently,0.0% of the company's shares are short sold. Currently,0.0% of the company's shares are short sold. Based on an average trading volume of 20,800 shares, the days-to-cover ratio is presently 0.5 days.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is owned by institutional investors.

Inventiva Stock Down 3.6%

Shares of NASDAQ IVA traded down $0.15 during midday trading on Friday, reaching $4.07. 17,202 shares of the company's stock were exchanged, compared to its average volume of 17,252. Inventiva has a 52-week low of $1.53 and a 52-week high of $4.36. The business's fifty day moving average price is $3.33 and its two-hundred day moving average price is $3.17.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.